vs
AtriCure, Inc.（ATRC）与Priority Technology Holdings, Inc.（PRTH）财务数据对比。点击上方公司名可切换其他公司
Priority Technology Holdings, Inc.的季度营收约是AtriCure, Inc.的1.7倍（$247.1M vs $141.2M），Priority Technology Holdings, Inc.净利率更高（3.6% vs 0.1%，领先3.5%），AtriCure, Inc.同比增速更快（14.3% vs 8.8%），过去两年AtriCure, Inc.的营收复合增速更高（10.2% vs 9.6%）
AtriCure是一家专注于心房颤动及相关心脏病症治疗的医疗设备企业，研发并生产创新外科手术工具与疗法，主要服务北美、欧洲、亚太地区的医院、心脏外科中心及医疗机构，为微创心脏手术提供高效可靠的适配解决方案。
Priority Technology Holdings, Inc.是一家聚焦信息技术领域的企业，业务围绕计算机、通信系统等相关信息设备展开，涵盖信息的创建、处理、存储、检索与传输等相关信息技术应用服务，依托计算机科学与工程技术支撑业务开展。
ATRC vs PRTH — 直观对比
营收规模更大
PRTH
是对方的1.7倍
$141.2M
营收增速更快
ATRC
高出5.4%
8.8%
净利率更高
PRTH
高出3.5%
0.1%
两年增速更快
ATRC
近两年复合增速
9.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $141.2M | $247.1M |
| 净利润 | $108.0K | $8.9M |
| 毛利率 | 77.4% | — |
| 营业利润率 | 23.0% | 13.6% |
| 净利率 | 0.1% | 3.6% |
| 营收同比 | 14.3% | 8.8% |
| 净利润同比 | — | 23.9% |
| 每股收益（稀释后） | $0.00 | $0.10 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ATRCPRTH
| Q1 26 | $141.2M | — | ||
| Q4 25 | $140.5M | $247.1M | ||
| Q3 25 | $134.3M | $241.4M | ||
| Q2 25 | $136.1M | $239.8M | ||
| Q1 25 | $123.6M | $224.6M | ||
| Q4 24 | $124.3M | $227.1M | ||
| Q3 24 | $115.9M | $227.0M | ||
| Q2 24 | $116.3M | $219.9M |
净利润ATRCPRTH
| Q1 26 | $108.0K | — | ||
| Q4 25 | — | $8.9M | ||
| Q3 25 | $-267.0K | $27.6M | ||
| Q2 25 | $-6.2M | $10.9M | ||
| Q1 25 | $-6.7M | $8.3M | ||
| Q4 24 | — | $7.2M | ||
| Q3 24 | $-7.9M | $10.6M | ||
| Q2 24 | $-8.0M | $994.0K |
毛利率ATRCPRTH
| Q1 26 | 77.4% | — | ||
| Q4 25 | 75.0% | — | ||
| Q3 25 | 75.5% | — | ||
| Q2 25 | 74.5% | — | ||
| Q1 25 | 74.9% | — | ||
| Q4 24 | 74.5% | — | ||
| Q3 24 | 74.9% | — | ||
| Q2 24 | 74.7% | — |
营业利润率ATRCPRTH
| Q1 26 | 23.0% | — | ||
| Q4 25 | 1.8% | 13.6% | ||
| Q3 25 | 0.2% | 15.6% | ||
| Q2 25 | -4.5% | 15.6% | ||
| Q1 25 | -4.8% | 14.5% | ||
| Q4 24 | -11.7% | 15.0% | ||
| Q3 24 | -6.4% | 16.8% | ||
| Q2 24 | -6.2% | 15.1% |
净利率ATRCPRTH
| Q1 26 | 0.1% | — | ||
| Q4 25 | — | 3.6% | ||
| Q3 25 | -0.2% | 11.4% | ||
| Q2 25 | -4.5% | 4.5% | ||
| Q1 25 | -5.5% | 3.7% | ||
| Q4 24 | — | 3.2% | ||
| Q3 24 | -6.8% | 4.7% | ||
| Q2 24 | -6.9% | 0.5% |
每股收益（稀释后）ATRCPRTH
| Q1 26 | $0.00 | — | ||
| Q4 25 | $0.04 | $0.10 | ||
| Q3 25 | $-0.01 | $0.34 | ||
| Q2 25 | $-0.13 | $0.14 | ||
| Q1 25 | $-0.14 | $0.10 | ||
| Q4 24 | $-0.33 | $-0.05 | ||
| Q3 24 | $-0.17 | $0.07 | ||
| Q2 24 | $-0.17 | $-0.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $146.2M | $77.2M |
| 总债务越低越好 | $61.0M | $1.0B |
| 股东权益账面价值 | $491.7M | $-100.4M |
| 总资产 | $644.0M | $2.4B |
| 负债/权益比越低杠杆越低 | 0.12× | — |
8季度趋势，按日历期对齐
现金及短期投资ATRCPRTH
| Q1 26 | $146.2M | — | ||
| Q4 25 | $167.4M | $77.2M | ||
| Q3 25 | $147.9M | $57.0M | ||
| Q2 25 | $117.8M | $50.6M | ||
| Q1 25 | $99.9M | $47.6M | ||
| Q4 24 | $122.7M | $58.6M | ||
| Q3 24 | $130.3M | $41.1M | ||
| Q2 24 | $114.0M | $34.6M |
总债务ATRCPRTH
| Q1 26 | $61.0M | — | ||
| Q4 25 | — | $1.0B | ||
| Q3 25 | $61.9M | $997.5M | ||
| Q2 25 | $61.9M | $917.0M | ||
| Q1 25 | $61.9M | $918.9M | ||
| Q4 24 | — | $920.9M | ||
| Q3 24 | $61.9M | $808.1M | ||
| Q2 24 | $61.9M | $809.0M |
股东权益ATRCPRTH
| Q1 26 | $491.7M | — | ||
| Q4 25 | $491.9M | $-100.4M | ||
| Q3 25 | $476.5M | $-110.3M | ||
| Q2 25 | $464.5M | $-146.1M | ||
| Q1 25 | $454.6M | $-158.3M | ||
| Q4 24 | $461.0M | $-166.8M | ||
| Q3 24 | $465.0M | $-165.8M | ||
| Q2 24 | $462.1M | $-172.1M |
总资产ATRCPRTH
| Q1 26 | $644.0M | — | ||
| Q4 25 | $654.2M | $2.4B | ||
| Q3 25 | $635.4M | $2.2B | ||
| Q2 25 | $608.8M | $2.0B | ||
| Q1 25 | $591.6M | $1.9B | ||
| Q4 24 | $609.3M | $1.8B | ||
| Q3 24 | $615.1M | $1.8B | ||
| Q2 24 | $597.3M | $1.7B |
负债/权益比ATRCPRTH
| Q1 26 | 0.12× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.13× | — | ||
| Q2 25 | 0.13× | — | ||
| Q1 25 | 0.14× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.13× | — | ||
| Q2 24 | 0.13× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $36.8M |
| 自由现金流经营现金流 - 资本支出 | — | $30.9M |
| 自由现金流率自由现金流/营收 | — | 12.5% |
| 资本支出强度资本支出/营收 | — | 2.4% |
| 现金转化率经营现金流/净利润 | — | 4.12× |
| 过去12个月自由现金流最近4个季度 | — | $75.1M |
8季度趋势，按日历期对齐
经营现金流ATRCPRTH
| Q1 26 | — | — | ||
| Q4 25 | $20.0M | $36.8M | ||
| Q3 25 | $26.7M | $36.1M | ||
| Q2 25 | $21.6M | $17.1M | ||
| Q1 25 | $-11.0M | $10.0M | ||
| Q4 24 | $5.8M | $23.8M | ||
| Q3 24 | $20.0M | $19.8M | ||
| Q2 24 | $7.4M | $28.7M |
自由现金流ATRCPRTH
| Q1 26 | — | — | ||
| Q4 25 | $18.4M | $30.9M | ||
| Q3 25 | $24.1M | $30.1M | ||
| Q2 25 | $19.0M | $9.2M | ||
| Q1 25 | $-13.2M | $4.9M | ||
| Q4 24 | $3.1M | $19.1M | ||
| Q3 24 | $16.4M | $14.5M | ||
| Q2 24 | $5.0M | $23.6M |
自由现金流率ATRCPRTH
| Q1 26 | — | — | ||
| Q4 25 | 13.1% | 12.5% | ||
| Q3 25 | 18.0% | 12.5% | ||
| Q2 25 | 13.9% | 3.8% | ||
| Q1 25 | -10.7% | 2.2% | ||
| Q4 24 | 2.5% | 8.4% | ||
| Q3 24 | 14.1% | 6.4% | ||
| Q2 24 | 4.3% | 10.7% |
资本支出强度ATRCPRTH
| Q1 26 | — | — | ||
| Q4 25 | 1.1% | 2.4% | ||
| Q3 25 | 1.9% | 2.5% | ||
| Q2 25 | 2.0% | 3.3% | ||
| Q1 25 | 1.8% | 2.3% | ||
| Q4 24 | 2.2% | 2.0% | ||
| Q3 24 | 3.1% | 2.3% | ||
| Q2 24 | 2.1% | 2.3% |
现金转化率ATRCPRTH
| Q1 26 | — | — | ||
| Q4 25 | — | 4.12× | ||
| Q3 25 | — | 1.31× | ||
| Q2 25 | — | 1.57× | ||
| Q1 25 | — | 1.20× | ||
| Q4 24 | — | 3.29× | ||
| Q3 24 | — | 1.87× | ||
| Q2 24 | — | 28.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ATRC
| Appendage management | $48.4M | 34% |
| Open ablation | $39.1M | 28% |
| Other | $25.0M | 18% |
| Pain management | $22.4M | 16% |
| Minimally invasive ablation | $6.4M | 5% |
PRTH
暂无分部数据
